Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > ¹ÙÀÌ¿À¸¶Ä¿ > Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1470)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (54)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (55)
¹ÙÀÌ¿ÀÀåºñ (323)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (53)
À¯ÀüÀÚ Ä¡·á/RNAi (100)
Àç»ýÀÇÇÐ (125)
Ç×ü/¸é¿ª (188)
½ÃÀ庸°í¼­

Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿

Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification

¸®¼­Ä¡»ç Insight Pharma Reports
¹ßÇàÀÏ 2007³â 06¿ù »óǰÄÚµå 52986
ÆäÀÌÁö Á¤º¸ 234 pages
°¡°Ý
US $ 1,498 £Ü 1,696,700 PDF by E-mail ( Single User License)
US $ 1,875 £Ü 2,123,800 PDF by E-mail (Single Site License)


Insight Pharma Reports ¿¡¼­ 2007³â 06¿ù ¿¡ ¹ßÇàÇÑ ¡¸Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿¡¹ º¸°í¼­´Â 234 pages·Î ±¸¼ºµÇ¾î, US $1,498 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀº °ú°Å 10³â°£ ±ØÀûÀÎ ¼ºÀåÀ» ÀÌ·ç¾úÀ¸¸ç À̰ÍÀº »õ·Î¿î ¿À¹Í½º ±â¼úÀÇ È®¸³°ú »õ·Ó°í Å×½ºÆ® µÇÁö ¾ÊÀº ÀǾàǰ Ç¥ÀûÀÇ ÀÌ¿ë Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¼±À¸·Î ÀÎÇÑ Ã¼¿Ü Áø´Ü½ÃÇèÀÇ ±âȸ°¡ ¸¹¾Æ Áø °ÍÀÌ ÀÌÀ¯¶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ºÐ¾ßÀÇ Á¶»ç¿¡¼­ ¼¼°èÀûÀÎ Æò°¡¸¦ ¹Þ°í ÀÖ´Â ¹Ì±¹ÀÇ Á¶»çȸ»ç Insight Pharma Reports(º»»ç : ¸Þ»çÃß¼¼½ºÁÖ)¿¡¼­´Â Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ Á¶»ç ºÐ¼® º¸°í¼­ "Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification"¸¦ ¹ßÇàÇß½À´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¿ä¿Í ±â¼ú µ¿Çâ, ¼ÒÁ¤ÀÇ Ä¡·á ºÐ¾ßÀÇ µ¿Çâ, ½ÃÀå ºÐ¼®, °³¹ß µ¿Çâ, Àü¹®°¡ÀÇ ÀÎÅÍºä °á°ú µîÀ» ÀüÇØµå¸³´Ï´Ù.

    Á¦ 1 Àå ¼­·Ð
    • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Á¤ÀÇ
    • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Á¾·ù
    • Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿
    • â¾à ¹× ½Å¾à °³¹ßÀÇ ¹ÙÀÌ¿À¸¶Ä¿
    • º¸°í¼­ÀÇ ±¸¼º
    Á¦ 2 Àå ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Å½»ö°ú ºÐ¼® ±â¼ú
    • ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®ÀÇ °¨¼ö¼º, Ư¼ö¼º, ¿¹Ãø¼º
    • ÇÁ¸®°Ô³ð ¹ÙÀÌ¿À¸¶Ä¿ ±â¼ú
      • È¿¼Ò ¹× ´ë»ç»ê¹° ºÐ¼®
      • ¸é¿ª Áø´Ü
      • ºÐÀÚ Áø´Ü
    • Æ÷½ºÆ® °Ô³ð ¹ÙÀÌ¿À¸¶Ä¿ ¹× ±â¼ú
      • Àü»çüÇÐ(Transcriptomics)
      • ÇÁ·ÎÅ׿À¹Í½º
      • ¸ÞŸº¼·Î¹Í½º
    Á¦ 3 Àå ¼ÒÁ¤ÀÇ Ä¡·áºÐ¾ßÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ÁøÈ­
    • ¾Ï
    • ½Å°æ Áúȯ
    • ½ÉÇ÷°ü ¹× ´ë»ç¼º Áúȯ
    • ÀÚ±â¸é¿ª ¹× ¿°Áõ¼º Áúȯ
    • ±âŸ
    Á¦ 4 Àå ½ÃÀå ÅõÀÔ Àü ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß
    • PhRMA/NIH/FDA ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ÄÁ¼Ò½Ã¾ö
    • EUÀÇ Á¦7ȸ ÇÁ·¹ÀÓ ¿öÅ© ¹ÙÀÌ¿À¸¶Ä¿ ÇÁ·Î±×·¥
    • ±âŸ ÄÁ¼Ò½Ã¾ö
    Á¦ 5 Àå ½ÃÀå µ¿Çâ
    • ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö°ú °³¹ßÀÇ ¼½Åͺ° µ¿Çâ
      • ¿ªÇаèÀÇ ¿ªÇÒ
      • ÀǾàǰ ¾÷°è ¹× »ý¹°Á¦Á¦ ±â¾÷ÀÇ ¿ªÇÒ
      • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀÇ ¿ªÇÒ
      • Áø´Ü¾÷°èÀÇ ¿ªÇÒ
      • ±ÔÁ¦ µ¿Çâ
    • ¾ÏÀ» À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ÅøÀ» °³¹ßÇϱâ À§ÇÑ ±ÇÀå »çÇ×
      • ¹ÙÀÌ¿À¸¶Å©¸¦ Ž»ö, °³¹ßÇϱâ À§ÇØ ÇÊ¿äÇÑ ¹æ¹ý, Åø, ¸®¼Ò½º
      • ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß¿¡ ÇÊ¿äÇÑ °¡À̵å¶óÀÎ, Ç¥ÁØ, °¨½Ã ¹× Àμ¾Æ¼ºê
      • ÀÓ»ó Æò°¡¿Í µµÀÔ¿¡ ÇÊ¿äÇÑ ¹æ¹ý°ú ÇÁ·Î¼¼½º
    • ¹ÙÀÌ¿À¸¶Ä¿¸¦ ü¿ÜÁø´ÜÀ¸·Î º¯È¯½Ãų ¶§ÀÇ ÇѰè
      • ±â¼úÀû ¹®Á¦
      • Àα¸ ¹®Á¦
      • ±ÔÁ¦ ¹®Á¦
    • °ü·Ã °Å·¡
    Á¦ 6 Àå Áúȯ °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿ Á¶»ç : 2007³â 3¿ù
    • Á¦¾àȸ»ç, »ý¹°Á¦Á¦ Á¦Á¶¾÷üÀÇ ´äº¯
    • Áø´Ü¾à, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ±â¾÷ÀÇ ´äº¯
    • Àüü °á·Ð
    Á¦ 7 Àå ÀÇ»ç °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Àü¹®°¡¿¡ ´ëÇÑ ÀÎÅͺä
    ºÎ·Ï
    µµÇ¥

cyj

Back to Top